in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
CPhI: Saltigo shuts US site, abandons plans to build potent API capacity
1:19 AM MDT | October 12, 2012 | Deepti Ramesh in Madrid
Saltigo (Langenfeld, Germany), a Lanxess subsidiary, says it has discontinued production at the company’s Redmond, WA, site and that it has abandoned a previously announced plan to produce potent active pharmaceutical ingredients (API) at that site. “We have decided to focus more on launched products or products in Phase 3 clinical trials and the Redmond site was involved in products required during phases 1 and 2. So we have decided not to continue our activities in the US,” Wolfgang Schmitz, CEO of Saltigo, told CW at the CPhI trade...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee